BIOMAT Database Logo BIOMAT Database Logo

Losartan for therapy of posttransplant erythrocytosis. 1997

J F Navarro, and M Macía, and J García

UI MeSH Term Description Entries
D008297 Male Males
D011086 Polycythemia An increase in the total red cell mass of the blood. (Dorland, 27th ed) Erythrocytosis,Erythrocytoses,Polycythemias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D057911 Angiotensin Receptor Antagonists Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR. Angiotensin II Receptor Antagonist,Angiotensin II Receptor Blocker,Angiotensin Receptor Antagonist,Angiotensin Receptor Blocker,Angiotensin II Receptor Antagonists,Angiotensin II Receptor Blockers,Angiotensin Receptor Blockers,Antagonist, Angiotensin Receptor,Antagonists, Angiotensin Receptor,Blocker, Angiotensin Receptor,Receptor Antagonist, Angiotensin,Receptor Antagonists, Angiotensin,Receptor Blocker, Angiotensin,Receptor Blockers, Angiotensin
D019808 Losartan An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol,Cozaar,DuP-753,Losartan Monopotassium Salt,Losartan Potassium,MK-954,MK954,DuP 753,DuP753,MK 954,Monopotassium Salt, Losartan,Potassium, Losartan,Salt, Losartan Monopotassium

Related Publications

J F Navarro, and M Macía, and J García
Treatment of posttransplant erythrocytosis with losartan.
August 1997, Transplantation proceedings,
J F Navarro, and M Macía, and J García
The effect of losartan on posttransplant erythrocytosis.
January 2001, Transplantation proceedings,
J F Navarro, and M Macía, and J García
Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis.
September 1999, Transplantation proceedings,
J F Navarro, and M Macía, and J García
Comparison of enalapril and losartan in the treatment of posttransplant erythrocytosis.
November 2000, Nephron,
J F Navarro, and M Macía, and J García
Enalapril: safe and effective therapy for posttransplant erythrocytosis.
February 1993, Transplantation proceedings,
J F Navarro, and M Macía, and J García
Posttransplant erythrocytosis.
April 2003, Kidney international,
J F Navarro, and M Macía, and J García
Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
June 2005, Transplantation proceedings,
J F Navarro, and M Macía, and J García
Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.
June 1998, Journal of the American Society of Nephrology : JASN,
J F Navarro, and M Macía, and J García
Factors inducing posttransplant erythrocytosis.
September 1997, European journal of medical research,
J F Navarro, and M Macía, and J García
Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis.
September 1997, Transplantation,
Copied contents to your clipboard!